Phase III, Parallel-group, Placebo Controlled, Double-blind, Randomized, Multicenter, International Study to investigate the safety and efficacy of ST261 (Propionyl-L-Carnitine Hydrochloride) modified release tablets in Patients Affected by mild Ulcerative Colitis under Oral Stable Treatment.

Trial Profile

Phase III, Parallel-group, Placebo Controlled, Double-blind, Randomized, Multicenter, International Study to investigate the safety and efficacy of ST261 (Propionyl-L-Carnitine Hydrochloride) modified release tablets in Patients Affected by mild Ulcerative Colitis under Oral Stable Treatment.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Propionyl carnitine (Primary) ; Aminosalicylic acids
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Leadiant Biosciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Feb 2017 According to a Leadiant Biosciences media release, this trial was originally conducted by Sigma-Tau Pharmaceuticals, Inc. but later on this company's name changed to Leadiant Biosciences
    • 09 Apr 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top